Share
965 Posts.
lightbulb Created with Sketch. 3
clock Created with Sketch. 20/08/14
22:04
Share
Originally posted by kpkg
↑
Chiasma=dfferent part of the acromegaly market as it was going after the space of the first line treatments which account for about 60% of the market. Second line treatment which is our space is the remaining 40% that fail these first line treatments.only the daily injection of Somavert as competition.
Expand
Just to add to your post kpkg - there is also the add-on study we're about to undertake which could, best case scenario, make 40% reduction seem small and result in dosing proportionate to body weight. I assume this study will be completed to confirm the approach prior to commencing phase 3.
